tbuckley/cabot-search huggingface dataset:
Public Comments and Industry Interests in Medicaid Coverage Decisions
Authors: Genevieve P. Kanter
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Authors: Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, Lydia Hammond, Ndiya Ogba
Journal: Journal of the National Comprehensive Cancer Network (2019)

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age &lt;60 years) and older (age ≥60 years) adult patients.
Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Authors: Chelsea C Pinnix, Jillian R Gunther, Bouthaina S. Dabaja, Sherry Adkins, Misha Hawkins, Jason R. Westin, Luis Fayad, Sairah Ahmed, Nathan H. Fowler, Fredrick B. Hagemeister, Swaminathan P. Iyer, Maria Alma Rodriguez, Hun Ju Lee, Raphael E Steiner, Ranjit Nair, Paolo Strati, Simrit Parmar, Felipe Samaniego, Michael Wang, Sattva S Neelapu, Loretta J. Nastoupil
Journal: Blood (2019)
Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV
Authors: Andrew D. Kerkhoff, Bianca Sossen, Charlotte Schutz, Elena Ivanova Reipold, Andre Trollip, Emmanuel Moreau, Samuel G. Schumacher, Rosie Burton, Amy Ward, Mark P. Nicol, Graeme Meintjes, Claudia M. Denkinger, Tobias Broger
Journal: European Respiratory Journal (2019)

<b>FujiLAM point-of-care rapid urine test for TB detects a large proportion of pulmonary and traditionally difficult-to-diagnose extra-pulmonary forms of TB in hospitalised patients with advanced HIV</b>http://bit.ly/36Dl0Eo
Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis
Authors: Vania T.M. Hungria, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, Bart Heeg, Annette Lam, Gerardo Machnicki, Jianming He, Mariana Fernandez
Journal: Blood (2019)
ACTR-47. PHASE-III TRIAL OF STANDARD CHEMOTHERAPY VS. CHEMOTHERAPY GUIDED BY CANCER STEM CELL TEST IN RECURRENT GLIOBLASTOMA (NCT03632135)
Authors: Tulika Ranjan, Dawit Aregawi, Christine Lu-Emerson, Jason Schroeder, Mark Anderson, Rekha Chaudhary
Journal: Neuro-Oncology (2019)

Abstract Stupp treatment protocol for patients with glioblastoma (GBM) has improved the median overall survival to 14.6 months. However, no investigations have defined effective strategies against recurrence and the prognosis of recurrent GBM patients remains poor. Personalized medicine with assay-guided treatment targeting chemotherapy resistant cancer stem cells (CSCs) alongside the bulk tumor cells is a new paradigm in cancer treatment that may result in improved patient’s outcome. We are using ChemoID, a CLIA and CAP certified CSC cytotoxicity assay for predicting response to chemotherapeutic agents. Our prospective analysis of 61 GBM patients demonstrated that ChemoID-guided treatment significantly improved tumor response. For every 5% increase in cell kill of CSCs by assay-guided chemotherapy, 12-month patient response (non-recurrence of cancer) increased 2.5-fold, OR=2.3 (p=0.01). We also found that median recurrence time was 20-months versus 3-months for patients with a positive (&gt;40% cell kill) CSC test versus negative, whereas median recurrence time was 13-months versus 4-months for patients with a positive (&gt;55% cell kill) bulk test versus negative. We are conducting a multi-institutional phase-III clinical trial (NCT03632135) to determine the clinical validity of the ChemoID assay as a predictor of clinical response in recurrent GBM. The study has been designed as a parallel group controlled clinical trial and the participants are randomized to either standard of care chemotherapy chosen by the physician or ChemoID-guided therapy. Response to therapy will be measured by MRI imaging using RANO criteria. Primary endpoint of median overall survival (OS) and secondary endpoints of OS at 6, 9, and 12 months, median progression free survival (PFS), PFS at 4, 6, 9, and 12 months, objective tumor response, time to recurrence, and quality of life will be measured. Trial is open and currently 22 subjects have been enrolled. Interim analysis of the trial will be conducted in approximately 12 months.
Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells
Authors: Xinyi Teng, Hao Zhang, Zuyu Liang, Mi Shao, Xiujian Wang, Lijuan Ding, Jiazhen Cui, Yongxian Hu, He Huang
Journal: Blood (2019)
After-effects of Modern Treatment of Carcinoma
Authors: P. Furnivall
Journal: BMJ (1938)

In autoimmune Graves’ disease (GD), autoantibodies bind to the thyrotropin receptor (TSHR) and cause hyperthyroidism. We studied the effects of fms-like tyrosine kinase receptor 3 ligand (Flt3-L) or GM-CSF treatment on the development of experimental autoimmune GD (EAGD) in mice, a slowly progressing Ab-mediated organ-specific autoimmune disease of the thyroid induced by immunization with syngeneic cells expressing TSHR. Flt3-L and GM-CSF treatment resulted in up-regulation of CD8a<sup>+</sup> and CD8a<sup>−</sup> dendritic cells, and skewing of cytokine and immune responses to TSHR in favor of Th1 and Th2, respectively. However, this skewing did not persist until the later stages, and thus failed to affect the course or severity of the disease. To determine whether the total absence of either IL-4 or IFN-γ could affect the development of EAGD, we immunized wild-type, IFN-γ<sup>−/−</sup> and IL-4<sup>−/−</sup> BALB/c mice with TSHR. Nearly 100% of the wild-type and IFN-γ<sup>−/−</sup> mice developed EAGD with optimal TSHR-specific immune responses, while IL-4<sup>−/−</sup> mice completely resisted disease and showed delayed and suboptimal pathogenic Ab response. These data demonstrated that skewing immune responses to TSHR, using either Flt3-L or GM-CSF, in favor of Th1 or Th2, respectively, may not be sufficient to alter the course of the disease, while the complete absence of IL-4, but not IFN-γ, can prevent the development of EAGD.
PDTM-09. Yap1 FUNCTION IN SEX-BIASED MEDULLOBLASTOMA FORMATION AND ANTI-TUMOR IMMUNITY
Authors: Nourhan Abdelfattah, Sivaraman Natarajan, Yaohui Chen, Kin-Hoe Chow, Shu-hsia Chen, James Olson, David Baskin, Kyuson Yun
Journal: Neuro-Oncology (2019)

Abstract Immunotherapies offer remarkable potential to provide robust therapeutic benefit. Patients suffering from medulloblastoma (MB), the most frequent pediatric brain malignancy, can especially benefit from this approach, minimizing the devastating side effects of aggressive radiation and chemotherapies that disrupt normal brain development. However, regulators of the immune landscape remain poorly understood and no effective immunotherapies exist yet for MB. Here, we describe a sex-dependent Yap1 function in fSmoM2;GFAPcre SHH-MB (SG) mouse model. We show that Yap1 is both a cell-autonomous regulator of MB stem-cells and a non-cell-autonomous regulator of immune infiltrates in SHH-MB. Yap1 deletion in SG mice results in increased neuronal differentiation, significantly extended survival, and enhanced infiltration of peripheral blood immune cells (including cytotoxic T-cells, neutrophils, and macrophages). Additionally, this rescue phenotype is observed in a sex-biased manner: 65% of Yap1f/f;fSmoM2;GFAPcre males are rescued in contrast to 35% of females. These observations implicate Yap1 as a mediator of sex-biased brain-tumor formation, either through direct modulation of MB cells and/or through indirectly mediating the MB immune landscape. We are currently testing the role of sex-specific differences in the developing mouse brain to elucidate context-dependent function of Yap1 in MB genesis and maintenance.
Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, William G. Wierda, Deborah A. Thomas, Guillermo Garcia-Manero, Gautam Borthakur, Sherry Pierce, Jorge Cortes
Journal: Blood (2008)
Repetitive Elements Enhance Hematopoietic Regeneration Via Activation of the Innate Immune Receptor MDA5
Authors: Thomas Clapes, Aikaterini Polyzou, Pia Prater, Sagar Sagar, Barbara Hummel, Daniel Maticzka, Stylianos Lefkopoulos, Ibrahim Ilik, Lheanna Klaeyle, Rolf Backofen, Asifa Akhtar, Ritwick Sawarkar, Dominic Grun, Eirini Trompouki
Journal: Blood (2019)
CBMT-26. SERIAL CHARACTERIZATION OF HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GLIOMA AND THE INFLUENCE OF BEVACIZUMAB
Authors: Adam Autry, Jeremy Gordon, Hsin-Yu Chen, Marisa Lafontaine, Javier Villanueva-Meyer, Susan Chang, Duan Xu, Peder Larson, Daniel Vigneron, Yan Li
Journal: Neuro-Oncology (2019)

Abstract Treatment-related changes often mimic or mask tumor on standard anatomic imaging, making it difficult to monitor disease recurrence. Hyperpolarized (HP) carbon-13 MR imaging allows for real-time non-invasive measurement of metabolism, which may improve patient surveillance. Here, we focused on characterizing serial HP scans in patients undergoing treatment compared to healthy controls. Serial dynamic HP C-13 MRI scans were performed on 5 patients with recurrent glioma (22 total) and 3 healthy controls (4 total) using an echo-planar imaging sequence (2.88-8cm3 spatial resolution, 3s temporal resolution, 60s), following injection of 0.43mL/kg of 250mM HP [1-13C]pyruvate. Apparent rate constants were modeled for enzymatic conversion of pyruvate-to-lactate (kPL) via cytosolic lactate dehydrogenase and pyruvate-to-bicarbonate (kPB) via mitochondrial pyruvate dehydrogenase and carbonic anhydrase. Regions of interest included normal-appearing white matter (NAWM) and T2-hyperintense lesions (T2L), which were segmented from H-1 MR images and then aligned to the HP data. Carbon voxels containing &gt;30% of NAWM or T2L were included in the analysis. Healthy controls demonstrated consistent kPL and kPB values over 4 scans in NAWM with SD/Mean of 5% and 12%, respectively. Compared to the median kPL-NAWM of 0.022s-1 in controls, the 5 patients had median serial kPL-NAWM values of 0.023, 0.023, 0.023, 0.029, and 0.015s-1, and mean serial ratios of kPL between T2L and NAWM (kPL-T2L/kPL-NAWM) of 1.22, 1.27, 1.05, 1.32, and 1.37s-1, indicating higher values in putative tumor. Median kPB-NAWM in controls was 0.004s-1 and ranged in patients 0.003-0.006s-1. Two patients with &gt;4 serial scans, showed consistent kPL-NAWM over standard-of-care treatment and elevated kPL-T2L within new lesions, but up to 85% increase in kPL-NAWM with bevacizumab, which may be attributed to reduced BBB permeability. Stable patients generally demonstrated consistent kPL-T2L values that were lower compared to progressive patients. Future studies will include multi-parametric 1H imaging analysis in a larger patient population.
GENE-42. EXOME SEQUENCING ANALYSIS TO IDENTIFY POSSIBLE GENOMIC DRIVERS OF METASTATIC INVASION INTO THE SPINE
Authors: Alexandra Calinescu, Zain Sultan, Sabrina Rocco, Chris Gates, Gregory Clines, Nicholas Szerlip
Journal: Neuro-Oncology (2019)

Abstract The spine is a common site of metastatic spread of many cancers, causing debilitating pain and suffering. Treatment of spinal metastases is limited by resistance to radiation, chemotherapy, and proximity to the spinal cord. It is currently not known what causes the high incidence of spinal metastases, yet theories have been proposed, like the venous metastatic spread theory (Batson, 1940) and the “seed and soil” hypothesis (Paget, 1889), postulating that factors intrinsic to the tumor cells or to the microenvironment determine the location of cancer dissemination. Recent advances in high throughput sequencing allow for in depth analyses of the molecular signatures of tumors. To identify if there are intrinsic genetic alterations common to cancer cells that disseminate into the spine, we sequenced the exome of metastatic tumor cells harvested from the vertebrae of 9 patients with different primary tumors: carcinomas and sarcomas. Exome sequencing was performed using the HiSeq 4000 (Illumina) platform on DNA from tumor cell lines and control blood or bone marrow. Data was analyzed at the University of Michigan Bioinformatics Core and variants were called using the VarScan method (http://varscan.sourceforge.net/) in somatic mode. This analysis identified a total of 2366 genes with high impact mutations (888–1026 per sample); of these, 232 genes are common to all patients analyzed. Ninety-six of the identified genes (4%) are included in the Catalogue of Somatic Mutations in Cancer, and of these, seven: ACSL6, ACVR1, ALK, FGFR2, HSP90AA1, PTPN6 and PTPRB, have high impact mutations in all 9 patients with spinal metastatic disease. Pathway analysis of genes mutated in 5 or more patients shows significant overrepresentation of 41 KEGG pathways including TGFb, HIF1-a, VEGF, Wnt and Estrogen signaling pathways. Ongoing experiments are performed to validate the sequencing analysis and characterize functional consequences of the common mutations identified.
Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Hong-Hui Huang, Jian Hou, Yang-Ming Zhang, Yu-Bo Zhou, Li Jia, Fa-Jun Nan
Journal: Blood (2019)
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration
Authors: David M. Kent, David van Klaveren, Jessica K. Paulus, Ralph D'Agostino, Steve Goodman, Rodney Hayward, John P.A. Ioannidis, Bray Patrick-Lake, Sally Morton, Michael Pencina, Gowri Raman, Joseph S. Ross, Harry P. Selker, Ravi Varadhan, Andrew Vickers, John B. Wong, Ewout W. Steyerberg
Journal: Annals of Internal Medicine (2019)

The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement was developed to promote the conduct of, and provide guidance for, predictive analyses of heterogeneity of treatment effects (HTE) in clinical trials. The goal of predictive HTE analysis is to provide patient-centered estimates of outcome risk with versus without the intervention, taking into account all relevant patient attributes simultaneously, to support more personalized clinical decision making than can be made on the basis of only an overall average treatment effect. The authors distinguished 2 categories of predictive HTE approaches (a "risk-modeling" and an "effect-modeling" approach) and developed 4 sets of guidance statements: criteria to determine when risk-modeling approaches are likely to identify clinically meaningful HTE, methodological aspects of risk-modeling methods, considerations for translation to clinical practice, and considerations and caveats in the use of effect-modeling approaches. They discuss limitations of these methods and enumerate research priorities for advancing methods designed to generate more personalized evidence. This explanation and elaboration document describes the intent and rationale of each recommendation and discusses related analytic considerations, caveats, and reservations.
Vitamin B<sub>12</sub> Therapy in Older Adults and Misconception of Its Inappropriateness
Authors: Nathan M. Stall, Barry J. Goldlist, Shabbir M. H. Alibhai
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source
Authors: Pallavi Mehta, Stalin Ramprakash, C Raghuram, Deepa Trivedi, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, Rajat Kumar Agarwal, Lawrence Faulkner
Journal: Blood (2019)
ATIM-39. PHASE 2 OPEN-LABELED STUDY OF ADJUVANT TEMOZOLOMIDE PLUS TUMOR TREATING FIELDS PLUS PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)
Authors: David Tran, Sonisha Warren, Anne Allen, Deborah Sampson, Dongjiang Chen, Nagheme Thomas, Valerie Greene, Maryam Rahman, Ashley Ghiaseddin
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND/OBJECTIVE Tumor treating Fields (TTFields) plus maintenance temozolomide is an approved standard treatment for newly diagnosed Glioblastoma (GBM). TTFields are alternating electric fields of low intensity and intermediate frequency delivered non-invasively via transducer arrays to tumor region. Immune checkpoints have not been studied widely in newly diagnosed GBM patients. TTFields combined with temozolomide elicit anti-mitotic effects on proliferative cancer cells and augment recruitment of immune effector cells specific for glioma cells to the tumor microenvironment where pembrolizumab further potentiates the immune reaction to achieve a synergistic therapeutic effect. This study [NCT03405792] will determine if adding pembrolizumab to TTFields and maintenance temozolomide (triple combination) increases progression-free survival (PFS) in patients with newly diagnosed GBM versus historical control (EF-14). METHODS This study will enroll patients (N=24) with pathologic diagnosis of newly diagnosed GBM WHO grade 4, &gt; 18 years after maximal surgery or biopsy followed by radiation therapy with adjuvant temozolomide (Stupp protocol). The primary endpoint is increases in PFS compared to historical control data (EF-14). Secondary endpoints include: toxicity and tolerability of the triple combination; overall survival and response rates versus historical data; augmentation of TTFields-initiated glioma-specific immune reaction by pembrolizumab. Exploratory endpoints include: metabolomics signature of immune activation by TTFields and TTFields plus pembrolizumab in serum and urine, and correlation of mutation burden in primary tumor samples with response to pembrolizumab plus TTFields. We assumed an accrual period of 12 months, an accrual rate of 2 patients per month, an additional 18 months of follow-up, and proportional hazards. Per shape parameter estimate of k=0.88 with empirical 95% confidence interval (0.82, 0.95) obtained via simulation of historical control data, a sample size of 24 patients should detect an improvement in PFS of 6 to 8 months with 80% power and a 1-sided significance level of 0.05 (Wu and Xiong, 2014).
Abstract 14975: Transitioning Parenteral Prostacyclin Analogs to Selexipag in Pulmonary Arterial Hypertension
Authors: Nicholas J Shelburne, Kishan S Parikh, Karla Kennedy, Talal Dahhan, Terry Fortin, Sudarshan Rajagopal
Journal: Circulation (2018)

Introduction: Selexipag, an oral selective prostacyclin receptor agonist, delays disease progression versus placebo in pulmonary arterial hypertension (PAH). In appropriate patients, transitioning ...